openPR Logo
Press release

Global Hemophilia Treatment Market to 2024

11-16-2017 07:44 PM CET | Health & Medicine

Press release from: Optima insights Pvt Ltd

/ PR Agency: optima insights
Hemophilia Treatment

Hemophilia Treatment

Market Overview, Key in-line Products, Market Share Distribution, Competitive Dynamics, Regulatory Outlook, Pipeline Development, Growth Catalysts & Challenges, Leading Market & R&D Trends, Partnership & Deals Analyses, Global Sales forecast of in-line and pipeline products, Fast Growing Private Companies, Management Perspectives, Commentaries, Market Outlook & Summary Conclusions

Global hemophilia treatment market was valued at $10.2bn in 2015 and is forecast to grow at a modest 5.4% CAGR between 2015 and 2024, culminating in 2024 global sales of $17.2bn.

Request For TOC : http://optimainsights.org/request-toc/global-hemophilia-treatment-market-to-2024

Hemophilia is a rare inherited bleeding disorder whereby blood does not clot normally. Predominantly, hemophilia is classified as hemophilia A and hemophilia B. Hemophilia A occurs when the body is unable to produce adequate amounts of factor VIII (FVIII), while patients with hemophilia B are unable to produce adequate amounts of factor IX (FIX).

Based on patient numbers and market opportunity, hemophilia A is the largest market, followed by hemophilia A patients that need bypassing agents to treat their disease. Hemophilia B is the third largest segment. Rare bleeding disorders, such as Von Willebrand disease, make up the remainder of the total hemophilia treatment market.

Global Hemophilia Treatment Market, By Types, 2013 - 2024 (USD Million)

“Treatment Algorithm”

The current treatment paradigm for most hemophilia patients remains predominantly first generation recombinant factor replacement therapies. Recombinant products now represent two third of the market. Prior to the development of recombinant technologies, plasma derived therapies remained the standard of care. Some patients have elected to switch to extended half-life factor replacement products which have recently entered the market and are expected to gain strong adoption over the next 5 years. Shire’s Adynovate and Biogen’s Eloctate are currently approved extended half-life products.  There is also a small subset of patients, ~10% of the market who have elected to remain on plasma derived therapies.

 Consultants view lower inhibitor formation and less frequent infusions as the biggest unmet needs in hemophilia and are optimistic that longer-acting products that require less frequent dosing could represent an improvement.

"Shire Baxalta, Baxter, Biogen, Novo Nordisk, Pfizer and CSL are some of the key players in hemophilia treatment market"

In June 2016, Shire merged with Baxalta, giving Shire an attractive hemophilia product portfolio. Shires’ hemophilia franchise includes a strong breadth of products such as Advate, Feiba, Rixubis, Obizur, and plasma derived factors, such as Hemofil.

Shire’s Advate, acquired from Baxalta reported worldwide sales of ~$2bn in sales in 2015. Shire is expected to hold market leading position for the treatment of hemophilia A over the next 5 years supported by breadth of its hemophilia product franchise.

Novo Nordisk holds formidable position in the hemophilia market represented by its inhibitor treatment NovoSeven followed by Pfizer’s Benefix and Xyntha/Refacto, Bayer’s Kogenate, Biogen’s Eloctate and Alprolix, and CSL’s Helixate.

 “Reimbursement coverage and Payer Insights”

Given that recombinant factor replacement therapies to treat hemophilia command a high price (well over $100K/year for an annual cost of prophylaxis treatment) and have favorable reimbursement, these therapies take modest price increases per year. The extended half-life products that have entered the market have come in at a premium to older factor replacement therapies on an annual cost of therapy basis, despite the less frequent dosing requirements.

“New Product Innovations”

The hemophilia market has grown at a steady pace over the last 5 years and is expected to grow for next several years driven by greater prophylaxis treatment in the adult and pediatric populations, and new extended half-life factor replacement therapies entering the market.

Bayer is expected to file its extended half-life FVIII product BAY94-9027 in late 2016 and Novo Nordisk is expected to file its extended half-life product N8-GP in 2018. Once approved, these products can gradually gain more share of this market over the next decade.

Completely new approaches to the treatment of hemophilia, such as Roche/Chugai’s bispecific FIXa/X antibody ACE910 administered subcutaneously, could ultimately change the landscape for hemophilia treatment, but more data is needed in Phase III studies to ensure optimal dosing, long-term durability of therapy, and long-term safety with this approach can be achieved.
http://optimainsights.org/request-toc/global-hemophilia-treatment-market-to-2024

Chucks G
Sr.Manager International Sales
Phone: +1 424 2554 365
Email: info@optimainsights.org

Optima Insights is an innovative research and insights-driven enterprise committed to offering actionable intelligence to the global life science and healthcare market. We believe that meaningful insights and improved strategic content hold the key to improved ROI for our clients. We strike an innovative engagement model with our clients to Co-Create Intelligence that would address very specific issues facing them within their functional areas. We continuously support clients through the entire journey map to enable them to take better business decisions towards attaining market leadership.

Chucks G
Sr.Manager International Sales

Phone: +1 424 2554 365
Email: info@optimainsights.org

This release was published on openPR.

Permanent link to this press release:

Copy
Please set a link in the press area of your homepage to this press release on openPR. openPR disclaims liability for any content contained in this release.

You can edit or delete your press release Global Hemophilia Treatment Market to 2024 here

News-ID: 820767 • Views: 502

More Releases from Optima insights Pvt Ltd

Endometriosis Treatment Market is Expected to Reach $3.43 bn by 2027
The Endometriosis Treatment Market was valued at US $2.64 billion in the year 2019 and is estimated to reach US $3.43 billion by 2027, at a CAGR of 3.36%. The growth of tissue outside the uterus similar to lining of uterus (endometrium) refers to Endometriosis. Areas of endometrial tissue growth often occur in ovaries, fallopian tubes, peritoneum and outer surfaces of bladder, uterus, intestines, and rectum and rarely spread beyond pelvic
Inflammatory Bowel Disease (IBD) Treatment Market is Expected to Reach $15.5 bn …
The Inflammatory Bowel Disease (IBD) treatment market share was US$ 11.38 Bn in the year 2018. The market is anticipated to grow at a rate of 3.94%, through the forecast period to reach US$ 15.5 Bn by the year 2027. Inflammatory Bowel Disease (IBD) usually denotes disorders characterized by the inflammation in the digestive system. Inflammatory Bowel Disease (IBD) and Irritable Bowel Syndrome are two different disorders that are often confused
Polycystic Ovarian Syndrome (PCOS) Treatment Market is Expected to Reach $5.59 b …
The Polycystic Ovarian Syndrome (PCOS) Treatment Market was valued at US $3.74 billion in the year 2019 and is estimated to reach US $5.59 billion by 2027, at a CAGR of 5.18%. Polycystic Ovarian Syndrome (PCOS), also referred to as Stein-Leventhal syndrome is a hormonal disorder characterized by enlarged ovaries and formation of numerous small cysts (fluid-filled sacs) on the outer edges of the ovaries. Symptoms of PCOS include irregular periods,
Veterinary Vaccines Market is Expected to Reach $13.51 bn by 2027
The Veterinary Vaccines Market was valued at US $7.91 billion in the year 2018 and is estimated to reach US $13.51 billion by 2027, at a CAGR of 6.13%. Generally, vaccines are effective in preventing infectious diseases. Veterinary vaccines especially reduce the burden of the disease in animals and also helps in preventing several zoonotic diseases also. There are four types of veterinary vaccines available depending on preparation type, they are

All 5 Releases


More Releases for Hemophilia

Hemophilia Market
Hemophilia is an inherited genetic syndrome which impairs body-2019s capability to control blood clotting or coagulation. The episodes of bleeding mainly depend on the severity of hemophilia issue. There are two major kinds of hemophilia namely Hemophilia A & Hemophilia B. Hemophilia A is considered to be five times more prevailing as compared to hemophilia B. Occurrence of hemophilia A is found in one out of five or six thousand
Hemophilia Therapeutics Pipeline Analysis Overview
The study analysed that the hemophilia pipeline comprises of 53 drug candidates in different stages of development. The pipeline analysis based on route of administration of active drug candidates showed, that around most of the hemophilia drug candidates are being developed to be administered by intravenous route. Explore Full Report Description At@ https://www.psmarketresearch.com/market-analysis/hemophilia-therapeutics-pipeline-analysis Most of the pharma and biotech companies are developing the therapeutics for hemophilia in collaboration with educational institutes. In
Hemophilia Gene Therapy - A Pipeline Analysis Report
"The Report Hemophilia Gene Therapy - A Pipeline Analysis Report provides information on pricing, market analysis, shares, forecast, and company profiles for key industry participants. - MarketResearchReports.biz" Hemophilia Gene Therapy: An insight Hemophilia is an inherited bleeding disorder. The gene responsible for hemophilia is present on the X chromosome and is inherited in a recessive manner. Hemophilia A, also called as factor VIII (FVIII) deficiency or classic hemophilia, is caused by missing
Hemophilia B - Pipeline Review, H1 2017
ReportsWorldwide has announced the addition of a new report title Hemophilia B - Pipeline Review, H1 2017 to its growing collection of premium market research reports. Global Markets Direct's latest Pharmaceutical and Healthcare disease pipeline guide Hemophilia B - Pipeline Review, H1 2017, provides an overview of the Hemophilia B (Hematological Disorders) pipeline landscape. Hemophilia B is a hereditary bleeding disorder caused by a lack of blood clotting factor IX. Symptoms include
In-depth analysis of the Global Hemophilia Market: hemophilia A, hemophilia B, h …
Latest industry research report on: Global Hemophilia Market | Industry Size, Share, Research, Reviews, Analysis, Strategies, Demand, Growth, Segmentation, Parameters, Forecasts Request For Sample Report @ http://www.marketresearchreports.biz/sample/sample/1064504 The hemophilia market has entered into an era of unprecedented growth rate with a variety of treatment options. Development of new therapeutics along with expansion in the current treatment options has presented new opportunities to the market. Hemophilia being an inherited genetic bleeding disorder causes
Hemophilia Management Market: Latest Trends & Insights 2024
Transparency Market Research presents this most up-to-date research on "Hemophilia Management Market - Global Industry Analysis, Size, Share, Growth, Trends and Forecast 2016 - 2024" Hemophilia is an inherited bleeding disorder which prevents blood clotting. People born with hemophilia have little or no clotting factor. Clotting factor is a protein needed for normal blood clotting. There are several types of clotting factors. These proteins work with platelets to help the blood